Ustekinumab for Pediatric Ulcerative Colitis: What the FDA Approval Means for IBD Practice

For clinicians managing pediatric ulcerative colitis, one recurring question has remained difficult: what should be offered when a child with moderate-to-severe UC needs advanced therapy beyond conventional treatment, especially when anti-TNF therapy is not suitable, has failed, or is unlikely to be the preferred long-term strategy?

The U.S. Food and Drug Administration’s approval of Stelara, ustekinumab, for moderately to severely active ulcerative colitis in pediatric patients aged 2 years and older directly addresses part of that gap. The FDA announced the approval on August 28, 2026, and GI & Hepatology News reported the update on August 31, 2026. The same FDA notice states that ustekinumab had previously been approved on April 15, 2026, for moderately to severely active Crohn’s disease in pediatric patients aged 2 years and older. With both pediatric Crohn’s disease and pediatric ulcerative colitis indications in place, the FDA described ustekinumab as the first approved therapeutic monoclonal antibody that does not target tumor necrosis factor-alpha for the two main forms of pediatric inflammatory bowel disease.

This is a regulatory approval, not a new guideline recommendation. It should therefore be interpreted as an expansion of labeled therapeutic options rather than a mandate to reposition therapy for every child with ulcerative colitis. For gastroenterologists, pediatric IBD specialists, fellows, and researchers, the importance lies in the changing treatment landscape: pediatric UC is beginning to acquire mechanistic options beyond the anti-TNF class, but evidence interpretation still requires careful attention to study design, population, endpoints, and limitations.

The pediatric UC treatment gap behind the approval

Moderate-to-severe pediatric ulcerative colitis can be clinically demanding. Children and adolescents may present with bleeding, diarrhea, urgency, impaired quality of life, corticosteroid exposure, growth concerns, school disruption, and the psychological burden of chronic disease. The FDA’s condition summary describes pediatric inflammatory bowel disease as chronic inflammation of the digestive tract, with UC affecting the innermost lining of the large intestine and rectum and causing symptoms such as bleeding, diarrhea, and urgency.

In clinical practice, the therapeutic goal is not merely short-term symptom control. Pediatric IBD care must consider durable remission, steroid avoidance, mucosal healing, safety over years rather than months, adherence, growth and development, and transition into adult care. A newly approved biologic class option is therefore meaningful, but only if clinicians understand what the approval is supported by and what remains uncertain.

The GI & Hepatology News report notes that the approval adds to a small set of advanced therapies labeled for children with UC. It also places the update in context by noting that, as of a December 2025 discussion cited in that report, anti-TNF agents were described as the only FDA-approved biologic or advanced therapy for children with moderate-to-severe UC. That context explains why this approval is clinically notable: it creates a labeled non–anti-TNF monoclonal antibody option in pediatric UC.

What exactly was approved?

The approved therapy is Stelara, ustekinumab injection, for moderately to severely active ulcerative colitis in pediatric patients aged 2 years and older. The approval was granted to Janssen Biotech, Inc., and the FDA notice states that Stelara received Orphan Drug Designation for this indication.

Ustekinumab targets the p40 subunit shared by interleukin-12 and interleukin-23. GI & Hepatology News notes that the drug has been approved for adults with moderately to severely active UC since 2019. This mechanism is important because it distinguishes ustekinumab from TNF-alpha antagonists. The approval therefore expands pediatric UC treatment not only by adding another branded option, but by adding a different immunologic target within labeled pediatric care.

Clinicians should avoid overinterpreting this distinction. A different mechanism does not automatically mean superior efficacy, broader applicability, or better safety for every patient. It means there is now an FDA-approved pediatric UC indication for a monoclonal antibody outside the anti-TNF pathway, supported by the evidence package reviewed by the agency.

The evidence package: adult UC data, pediatric Crohn’s data, and UNIFI Jr

The FDA describes the pediatric UC approval as being supported by several evidence streams: adequate and well-controlled studies in adults with UC, pharmacokinetic and safety data from pediatric patients with Crohn’s disease aged 2 to 17 years, and additional safety, efficacy, and pharmacokinetic data from a 52-week study in 112 pediatric patients with UC aged 3 to 17 years.

That 52-week pediatric UC study is the phase 3 UNIFI Jr study, registered as NCT04630028. The published abstract is titled “P1154 Safety and efficacy of ustekinumab in paediatric ulcerative colitis (UC): Results from the phase 3 UNIFI Jr study.” It appeared in the Journal of Crohn’s and Colitis, Volume 20, Supplement 1, and was published on January 21, 2026.

The study evaluated ustekinumab in pediatric patients aged 2 to under 18 years, weighing at least 10 kg, with moderately to severely active ulcerative colitis. Eligibility included a baseline Mayo score of at least 6, a Mayo endoscopy subscore of at least 2, and inadequate response or intolerance to conventional or biologic therapy, or corticosteroid dependence.

This population is clinically relevant because it reflects children with active disease despite prior treatment challenges. However, the age range in the FDA-approved label begins at 2 years and older, while the FDA specifically describes the pediatric UC supportive study as including patients aged 3 to 17 years. This distinction should be noted when discussing the directness of evidence for the youngest approved patients.

How UNIFI Jr was designed

UNIFI Jr used a two-phase treatment structure. In induction, 112 patients received a single open-label intravenous induction dose of ustekinumab. At week 8, 109 patients were randomized in a 1:1 ratio to blinded subcutaneous maintenance therapy every 8 weeks or every 12 weeks for 44 weeks. Randomization was stratified by weight category and week-8 clinical response status. Dosing was based on body surface area for patients under 40 kg and weight tier for those 40 kg or above.

The primary endpoints were clinical remission at week 8 and clinical remission at week 52 among those who had a clinical response at week 8. Clinical remission was defined using Mayo subscores for stool frequency, rectal bleeding, and endoscopy, including no friability on endoscopy.

The design has immediate interpretive implications. The induction phase was open-label, and the week-52 remission analysis focused on induction responders. Therefore, the week-52 results describe outcomes among patients who had already demonstrated response by week 8, not the entire initially treated population in the same way that an intention-to-treat induction-to-maintenance analysis might be interpreted. This does not invalidate the findings, but it affects how clinicians should present expectations to families and trainees.

The pediatric UC population studied

The UNIFI Jr abstract reports that among the 112 enrolled patients, the median age was 14.0 years, 54.5% were female, and 60.7% were biologic-naive. Disease burden was substantial: the median PUCAI score was 55.0, 91.7% had moderate UC, the median Mayo score was 8.0, and 67.0% had extensive UC.

These baseline details matter. The trial population was predominantly adolescent, with active disease and a high proportion of extensive colitis. The biologic-naive majority also shapes interpretation of subgroup results. Clinicians should be cautious about generalizing the same magnitude of benefit to very young children, highly refractory biologic-experienced patients, or populations underrepresented in the trial.

At week 8, 79 patients achieved clinical response, becoming the induction responders for the key week-52 outcome analysis reported in the abstract.

Key efficacy findings and what they mean clinically

Among the 79 week-8 induction responders, 32 patients, or 40.5%, achieved clinical remission at week 52. The same number and percentage achieved endoscopic improvement and were corticosteroid-free for at least 90 days. Symptomatic remission was reported in 52 patients, or 65.8%, while clinical remission by PUCAI score below 10 was reported in 51 patients, or 64.6%. Histologic-endoscopic mucosal improvement was reported in 29 patients, or 36.7%.

These endpoints are clinically meaningful because pediatric UC management increasingly values more than symptomatic improvement. Endoscopic improvement, steroid-free status, and histologic-endoscopic outcomes all speak to deeper disease control, although the source abstract does not provide longer-term outcome correlations in this pediatric cohort.

The remission rate appeared higher in patients without prior biologic failures than in those with biologic failure: 47.2% versus 26.9% at week 52 among induction responders. GI & Hepatology News notes that confidence intervals overlapped for this subgroup comparison. Therefore, this should be interpreted as a signal rather than definitive proof that biologic-naive patients will experience superior outcomes. It is consistent with a common clinical pattern in IBD, where earlier advanced therapy exposure may be associated with better response, but this specific comparison should not be overstated from the reported subgroup data.

The abstract also reports that both every-8-week and every-12-week maintenance regimens were efficacious. The available source does not provide enough detail to determine individualized interval selection, escalation strategies, or comparative superiority between intervals. Those decisions should remain guided by the prescribing label, specialist judgment, disease severity, treatment response, safety, and local regulatory context.

Safety observations in the available source

The FDA lists the most common adverse reactions in pediatric patients with UC receiving ustekinumab as nasopharyngitis, headache, abdominal pain, influenza, fever, diarrhea, sinusitis, fatigue, and nausea.

In UNIFI Jr, serious adverse events occurred in 6.4%, or 7 of 109 patients, during maintenance therapy. The abstract reports that the most commonly reported serious adverse events were gastrointestinal disorders related to UC. It also states that adverse event rates were similar between the every-8-week and every-12-week groups, with treatment-emergent serious adverse events reported in 9.3% and 3.6% of patients, respectively. The investigators concluded that ustekinumab was well tolerated and that no new safety signals were identified.

This safety language should be presented carefully. “No new safety signals” in a 52-week study of 112 pediatric UC patients is reassuring but not equivalent to definitive long-term pediatric safety certainty. Pediatric IBD treatment often extends over many years. Rare adverse events, long-latency risks, comparative safety versus other biologics, and outcomes in very young children require ongoing pharmacovigilance and real-world follow-up.

What this approval changes in practice

The most immediate practice implication is that clinicians now have an FDA-approved non–anti-TNF monoclonal antibody option for children aged 2 years and older with moderately to severely active UC. This can affect treatment conversations, prior authorization pathways, and sequencing discussions in pediatric IBD clinics.

For pediatric gastroenterologists, the approval may be particularly relevant when families ask whether all biologic options are anti-TNF agents, when there is prior anti-TNF failure or intolerance, or when a mechanistically distinct option is clinically desirable. It also may reduce reliance on off-label extrapolation in selected patients, because ustekinumab now carries a pediatric UC indication.

However, this is not the same as saying ustekinumab should replace anti-TNF therapy as first-line biologic treatment in all pediatric UC patients. The source does not provide a head-to-head comparison against anti-TNF agents, vedolizumab, JAK inhibitors, IL-23 inhibitors, or other emerging therapies. It also does not establish an optimal sequencing algorithm. The appropriate conclusion is narrower: ustekinumab is now an approved option supported by an evidence package that includes adult UC trials, pediatric Crohn’s pharmacokinetic and safety data, and pediatric UC data from UNIFI Jr.

What clinicians should not conclude

Clinicians should not infer causation beyond what the study design supports. UNIFI Jr evaluated outcomes after ustekinumab treatment, but the induction phase was open-label, and the week-52 remission data highlighted in the news report are among induction responders. Without a placebo comparator for the full reported pathway in the abstract, clinicians should avoid framing the pediatric UC data as proving superiority over other therapies.

Clinicians also should not claim that ustekinumab is established as the best biologic for pediatric UC. The approval expands the labeled armamentarium; it does not settle comparative effectiveness.

Nor should the adult AGA UC guideline be applied directly to children. GI & Hepatology News explicitly notes that the AGA living guideline on pharmacological management of moderate-to-severe UC addresses adult outpatients and does not make recommendations for pediatric patients. The same report states that guideline panel members reviewed new UC evidence in July 2025 and March 2026 and issued no new or amended recommendations.

For fellows and trainees, this distinction is crucial. Regulatory approval, adult guideline positioning, and pediatric treatment algorithms are related but not interchangeable.

Strengths of the evidence supporting this update

Several strengths make this approval clinically meaningful. First, the FDA evidence package integrates multiple sources: adult UC studies, pediatric Crohn’s pharmacokinetic and safety data, and pediatric UC-specific data. This is a common and pragmatic strategy in pediatric drug development, where large, fully independent pediatric efficacy trials can be difficult.

Second, UNIFI Jr included objective and clinically relevant endpoints, including clinical remission, endoscopic improvement, steroid-free status, and histologic-endoscopic mucosal improvement. These outcomes align with modern treat-to-target thinking in IBD, although the source itself does not position the trial as a treat-to-target strategy study.

Third, the trial addressed a population with moderate-to-severe disease and prior conventional or biologic therapy challenges, or corticosteroid dependence. That makes the evidence more relevant than a study limited to mild disease or uncomplicated patients.

Limitations and evidence gaps

The most important limitation is study design. The induction dose was open-label, and the reported maintenance remission endpoint focused on week-8 responders. This makes clinical interpretation different from a fully placebo-controlled, treat-through trial design.

The sample size was also modest, with 112 patients entering induction and 109 randomized into maintenance. This is understandable in pediatric UC research, but it limits precision for subgroup analyses, rare safety events, and comparisons across dosing intervals.

Another limitation is generalizability. The median age was 14 years, meaning that adolescents were strongly represented. The FDA label includes children aged 2 years and older, but the pediatric UC study described by the FDA included patients aged 3 to 17 years. Clinicians should be careful when discussing direct evidence in the youngest children.

Long-term durability beyond one year remains an important question. Pediatric UC requires treatment plans that may span childhood, adolescence, and transition to adult care. The source supports 52-week efficacy and safety observations, but not multi-year persistence, long-term immunogenicity, growth-related outcomes, malignancy risk, infection risk over extended exposure, or comparative durability versus other advanced therapies.

Finally, the abstract includes extensive conflict-of-interest disclosures and notes medical writing assistance funded by Johnson & Johnson. These disclosures do not invalidate the data, but they are relevant for critical appraisal and transparent academic discussion.

Future research and implementation priorities

The approval raises several practical questions for future pediatric IBD research. Where should ustekinumab fit relative to anti-TNF therapy in biologic-naive pediatric UC? How should clinicians choose between mechanistic classes after biologic failure? Which baseline features predict response? Are there pediatric pharmacokinetic thresholds that can guide optimization? How durable are remission and endoscopic improvement beyond 52 weeks? What is the long-term safety profile in children who begin therapy early and remain exposed for years?

Implementation will also depend on access. Regulatory approval may support insurance coverage, but real-world adoption will vary across health systems, countries, formularies, and pediatric IBD programs. Multidisciplinary decision-making remains essential, particularly for children with severe disease, steroid dependence, growth concerns, infection risk, or prior biologic exposure.

Clinical Takeaway

The FDA approval of ustekinumab for moderately to severely active pediatric ulcerative colitis in patients aged 2 years and older is a meaningful regulatory development for pediatric IBD care. It introduces a labeled non–anti-TNF monoclonal antibody option for pediatric UC and follows the earlier 2026 pediatric Crohn’s disease approval.

The supporting evidence includes adult UC studies, pediatric Crohn’s pharmacokinetic and safety data, and the phase 3 UNIFI Jr pediatric UC study. In UNIFI Jr, among week-8 induction responders, 40.5% achieved clinical remission at week 52, 65.8% achieved symptomatic remission, 40.5% achieved endoscopic improvement, and 40.5% were corticosteroid-free for at least 90 days. Safety findings were described as showing no new signals over the 52-week study period.

For clinicians, the approval broadens treatment options but should not be overstated. It does not establish ustekinumab as superior to other advanced therapies, does not define the optimal sequencing strategy, and does not replace pediatric-specific guideline interpretation. It is best viewed as an important step toward a more diversified, mechanism-based pediatric UC treatment landscape, with ongoing need for comparative effectiveness, long-term safety, and real-world durability data.

Five key clinical takeaways

1. Ustekinumab is now FDA-approved for moderately to severely active pediatric UC in patients aged 2 years and older.

2. The approval makes ustekinumab a labeled non–anti-TNF monoclonal antibody option for both major forms of pediatric IBD.

3. The pediatric UC evidence includes the phase 3 UNIFI Jr study, in which 112 patients received open-label IV induction and week-8 responders entered blinded maintenance therapy.

4. Week-52 outcomes among induction responders were clinically meaningful, including clinical remission, symptomatic remission, endoscopic improvement, and corticosteroid-free status.

5. The approval broadens options but does not define treatment sequencing, prove superiority over other therapies, or replace pediatric IBD guideline-based decision-making.

Source reference and link

Primary regulatory source: U.S. Food and Drug Administration. “FDA Approves Stelara for Pediatric Ulcerative Colitis.” Published August 28, 2026.

News source: GI & Hepatology News. “FDA expands Stelara approval to pediatric ulcerative colitis.” Published August 31, 2026.

Supporting study abstract: De Greef E, Turner D, Russell RK, et al. “P1154 Safety and efficacy of ustekinumab in paediatric ulcerative colitis (UC): Results from the phase 3 UNIFI Jr study.” Journal of Crohn’s and Colitis. Volume 20, Supplement 1. Published January 21, 2026.